Airsculpt Technologies vs Starling Oncology
AIRS and STLN side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AIRS and STLN compare
Starling Oncology is the larger company, worth 5.9 times as much as Airsculpt Technologies ($357M against $60.3M).
Starling Oncology grew revenue faster over the last twelve months (34.6% versus −6.3% for Airsculpt Technologies).
Starling Oncology keeps more of each dollar of sales as profit, with a net margin of −5.7% compared with −6.4% at Airsculpt Technologies.
Starling Oncology scores higher on the StockData Score (8 against 4 for Airsculpt Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AIRS | STLN |
|---|---|---|
| Size and price | ||
| Market cap | $60.3M | $357M |
| Share price | $0.837 | $3.50 |
| Change, 1 year | −86.3% | 2.0% |
| Change, 5 years | −94.4% | −54.6% |
| Beta (5Y) | 2.47 | 1.69 |
| Employees | 330 | 641 |
| StockData Score | ||
| Total score | 4 | 8 (better) |
| Valuation score | 2 (better) | 1 |
| Growth score | 1 | 3 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.4× (better) | 0.6× |
| P/B | 0.6× | – |
| EV/EBITDA | 16.5× | – |
| P/FCF | – | 18.9× |
| FCF yield | −4.2% | 5.3% (better) |
| Growth | ||
| Revenue growth (TTM) | −6.3% | 34.6% (better) |
| Revenue growth, 5Y average | 19.3% | 21.8% (better) |
| Profitability | ||
| Gross margin | 60.2% | – |
| Operating margin | −4.7% | −3.4% (better) |
| Net margin | −6.4% | −5.7% (better) |
| FCF margin | −1.7% | 3.0% (better) |
| Return on equity | −10.1% | – |
| Return on invested capital | −4.2% (better) | −96.2% |
| Financial health | ||
| Debt / equity | 0.35 | – |
| Net debt / EBITDA | 4.33 | – |
| Interest coverage | −1.4× (better) | −2.0× |
| Current ratio | 0.85 | 1.11 (better) |
| Altman Z-score | 0.70 | 1.74 (better) |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Buyback yield | −52.5% | – |
| Shareholder yield | −52.5% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 63.3% | 43.4% |
| Held by insiders | 76.6% | 56.6% |
| Insider net buying, 12 months | $2.0M (better) | −$11.1M |
| Short interest, % of float | 19.1% | – |
Go deeper
- AIRS stock overview
- AIRS income statement
- AIRS valuation and score
- STLN stock overview
- STLN income statement
- STLN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.